J
Joerg Schubert
Researcher at Saarland University
Publications - 26
Citations - 2080
Joerg Schubert is an academic researcher from Saarland University. The author has contributed to research in topics: Rituximab & Transplantation. The author has an hindex of 12, co-authored 26 publications receiving 1924 citations.
Papers
More filters
Journal ArticleDOI
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh,Joerg Schubert,Marita Ziepert,Rudolf Schmits,Martin Mohren,Eva Lengfelder,Marcel Reiser,Christina Nickenig,Michael R. Clemens,Norma Peter,Carsten Bokemeyer,Hartmut Eimermacher,Anthony D. Ho,Martin Hoffmann,Roland Mertelsmann,Lorenz Trümper,Leopold Balleisen,Ruediger Liersch,Bernd Metzner,Frank Hartmann,Bertram Glass,Viola Poeschel,Norbert Schmitz,Christian Ruebe,Alfred C. Feller,Markus Loeffler +25 more
TL;DR: In a multivariate analysis that used six cycles of CHOP-14 without rituximab as the reference, and adjusting for known prognostic factors, all three intensified regimens improved 3-year event- free survival and progression-free survival.
Journal ArticleDOI
Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer,Paula Cramer,Raymonde Busch,Sebastian Böttcher,Jasmin Bahlo,Joerg Schubert,Karl H. Pflüger,Silke Schott,Valentin Goede,Susanne Isfort,Julia von Tresckow,Anna-Maria Fink,Andreas Bühler,Dirk Winkler,Karl-Anton Kreuzer,Peter Staib,Matthias Ritgen,Michael Kneba,Hartmut Döhner,Barbara Eichhorst,Michael Hallek,Stephan Stilgenbauer,Clemens-Martin Wendtner +22 more
TL;DR: Chemoimmunotherapy with BR is effective and safe in patients with previously untreated CLL, and 90.5% of patients were alive.
Journal ArticleDOI
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
Peter Hillmen,Petra Muus,Alexander Röth,Modupe Elebute,Antonio M. Risitano,Hubert Schrezenmeier,Jeff Szer,Paul Browne,Jaroslaw P. Maciejewski,Joerg Schubert,Alvaro Urbano-Ispizua,Carlos M. de Castro,Gérard Socié,Robert A. Brodsky +13 more
TL;DR: Eculizumab has a substantial impact on the symptoms and complications of PNH and results a significant improvement in patient survival, with no evidence of cumulative toxicity and a decreasing occurrence of adverse events over time.
Journal ArticleDOI
HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)
Pieter Sonneveld,Ingo G.H. Schmidt-Wolf,Bronno van der Holt,Laila el Jarari,Uta Bertsch,Hans Salwender,Sonja Zweegman,Edo Vellenga,Joerg Schubert,Igor Wolfgang Blau,Asiong Jie,Berna Beverloo,Dirk Hose,Anna Jauch,Helgi van de Velde,Martijn R. Schaafsma,Walter Lindemann,Marie José Kersten,Ulrich Duehrsen,Michel Delforge,Katja Weisel,Sandra Croockewit,Hans Martin,S. Wittebol,Christof Scheid,Gerard M. J. Bos,Marinus van Marwijk-Kooy,Pierre W. Wijermans,Henk M. Lokhorst,Hartmut Goldschmidt +29 more
TL;DR: The efficacy of bortezomib (B) during induction and maintenance on progression-free survival (PFS) in patients with newly diagnosed symptomatic MM, who were candidates for high-dose therapy, was evaluated.
Journal ArticleDOI
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy
Nigel H. Russell,Rolf M. Mesters,Joerg Schubert,Marc Boogaerts,Hans Erik Johnsen,Consuelo del Cañizo,Nigel Baker,Philippa Barker,Tomas Skacel,Norbert Schmitz +9 more
TL;DR: Pegfilgrastim (6 or 12 mg) was effective for mobilizing peripheral blood progenitors cells in patients with non-Hodgkin’s lymphoma and was generally well tolerated, and may aid the design of studies to clarify optimal dosing and leukapheresis with pegfilGrastim.